Prepared by R.R. Donnelley Financial -- EX-10.16(a)




 Exhibit 10.16(a) 

 

CONFIDENTIAL 
  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



 TASK ORDER 

MEDPACE Task Order Number: 13 

MEDPACE Project Number: CHS02142 

This Task Order, dated October 18, 2013, is between Medpace, Inc. (“MEDPACE”), and Coherus Biosciences,
Inc. (“SPONSOR”). 
 RECITALS: 

WHEREAS, MEDPACE and SPONSOR have entered into that certain Master Services Agreement dated January 23, 2012 (the “Master
Services Agreement”); and 
 WHEREAS, pursuant to the Master Services Agreement, MEDPACE has agreed to perform certain
Services in accordance with Task Orders from time to time entered into by the Parties and SPONSOR and MEDPACE now desire to enter into such a Task Order; and 

WHEREAS, MEDPACE and SPONSOR desire to engage Medpace to perform initial certain services (“Services”) as set forth
hereinafter in connection with a Phase 3, A Double Blind, Randomized, Parallel Group, Active Control Study to Compare the Efficacy and Safety of CHS 0214 DP Versus Enbrel® in Subjects
With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate (METEOR) (“Project”) , which is incorporated herein by reference; 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, the Parties hereby agree as follows: 

 

	 	1.	Scope of Work. MEDPACE shall perform the initial services set forth in Appendix A, any other documents attached to and specifically referenced in this Task Order and any other initial services agreed to by
both Parties (“Initial Services”). The Initial Services must be conducted in compliance with the bid proposal provided by MEDPACE on September 3, 2013. The bid proposal is incorporated herein by reference and made a part of this Task
Order. 

  

	 	2.	Compensation. For performance of these Services, SPONSOR shall pay to MEDPACE according to terms set forth in Appendix A and the bid proposal for other initial activities requested. The Parties agree that
[***]. After staff is assigned, [***]. 


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 1 of 16












	 	3.	Term. In addition to the termination rights provided in Section 6 of the MSA, upon execution by the Parties of a Task Order to provide the remaining Services for the Study, this Task Order #14 shall be
deemed terminated and superseded by such agreement. 

  

	 	4.	MSA. The provisions of the Master Services Agreement are hereby expressly incorporated by reference into and made a part of this Task Order. 


IN WITNESS WHEREOF, the Parties have hereunto signed this Task Order effective as of the day and year first written above. 

 

			
	MEDPACE, INC.
		
	Signature:	 	/s/ John Wynne


			
		
	By:	 	John Wynne
		 	            (print name)
		
	Title:	 	Executive Director
		 	Business Development Support
		
	Date:	 	Dec 6 2013

  

			
	COHERUS BIOSCIENCES, INC.
		
	Signature:	 	/s/ Dennis M. Lanfear


			
		
	By:	 	Dennis M. Lanfear
		 	            (print name)
		
	Title:	 	President & CEO
		
	Date:	 	12/4/2013

 List of Appendices: 

Appendix A: Scope of Work 
 Appendix B:
Timeline 
 Appendix B: Services, Budget 

Appendix C: Payment Schedule 

  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 2 of 16











 APPENDIX A: SCOPE OF WORK 
  

	1.1	PARAMETERS 

  

							
	 ITEM
	  	DESCRIPTION
		  	 	[	***] 	 	[***]
		  	 	[	***] 	 	[***]
	 [***]
	  	 	[	***] 	 	[***]
		  	 	[	***] 	 	[***]
		  	 	[	***] 	 	[***]
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	
	 [***]
	  	 	[	***] 	 	

  

	1.2	PROJECT START-UP 

  

											
	 [***]
	  	[***]	 	  	[***]	  	 ITEM
	  	 DESCRIPTION

	[***]	  				  		  	[***]	  	
		  	 	[***]	  	  		  	[***]	  	[***]
	[***]	  				  		  	[***]	  	[***]


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 3 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











													
		  	 	[***]	  	  				  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
	[***]	  				  				  	[***]	  	
	[***]	  				  				  	[***]	  	
		  	 	[***]	  	  				  	[***]	  	
	[***]	  				  				  	[***]	  	
	[***]	  				  				  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
	[***]	  				  				  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
	[***]	  				  				  	[***]	  	[***]


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 4 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











															
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		 	[***]	  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  				  	[***]	  	[***]
		 		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		 		  	 	[***]	  	  	 	[***]	  	  	[***]	  	
		 		  	 	[***]	  	  	 	[***]	  	  	[***]	  	


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 5 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











													
		 		  	[***]	  	 	[***]	  	  	[***]	  	
		 		  	[***]	  	 	[***]	  	  	[***]	  	
		 		  	[***]	  				  	[***]	  	[***]

  

	1.3	CLINICAL OPERATIONS 

  

													
	 [***]
	  	[***]	 	  	[***]	 	  	 ITEM
	  	 DESCRIPTION

		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	[***]
	[***]	  				  				  	[***]	  	
	[***]	  				  				  	[***]	  	
	[***]	  				  				  	[***]	  	
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 6 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











													
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  				  	 	[***]	  	  	[***]	  	[***]
	[***]	  				  				  	[***]	  	
	[***]	  				  				  	[***]	  	[***]
		  	 	[***]	  	  				  	[***]	  	

  

	1.4	CLINICAL MONITORING 

  

													
	 [***]
	  	[***]	 	  	[***]	 	  	 ITEM
	  	 DESCRIPTION

		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]
		  	 	[***]	  	  	 	[***]	  	  	[***]	  	[***]

  

	1.5	CLINICAL SAFETY 

  

											
	 [***]
	  	[***]	 	  	[***]	  	 ITEM
	  	 DESCRIPTION

		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]

  

	1.6	[***] SYSTEM 

  

									
	 [***]
	  	[***]	  	[***]	  	 ITEM
	  	
DESCRIPTION



  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 7 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











											
		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	

  

	1.7	DATA MANAGEMENT 

  

											
	 [***]
	  	[***]	 	  	[***]	  	 ITEM
	  	 DESCRIPTION

		  	 	[***]	  	  		  	[***]	  	[***]
	[***]	  				  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]
		  	 	[***]	  	  		  	[***]	  	[***]

  

	1.8	STATISTICAL ANALYSIS 

  

									
	 [***]
	  	[***]	  	[***]	  	 ITEM
	  	
DESCRIPTION



  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 8 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	











											
		  	 	[***]	  	  		  	[***]	  	[***]

  

	1.9	DATA SAFETY MONITORING BOARD 

  

											
	 [***]
	  	[***]	 	  	[***]	  	 ITEM
	  	 DESCRIPTION

		  	 	[***]	  	  		  	[***]	  	
	[***]	  				  		  	[***]	  	


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 9 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

APPENDIX B: TIMELINE 
  

					
	 TASK
	  	DATE	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 10 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

APPENDIX C: SERVICES AND BUDGET 

SERVICES & BUDGET: 
  

					
	 Service Category
	  	Direct Fees (USD)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 11 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

 

					
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
		  	  
	  
	 
	 Total Direct Fees
	  	 	[***]	  
		  	  
	  
	 

  

					
	 Pass-Through/Pre-Funded Services
	  	PT/PF Fees (USD)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
		  	  
	  
	 
	 Total Pass-Through/Pre-Funded Services
	  	 	[***]	  
		  	  
	  
	 


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 12 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

APPENDIX D: PAYMENT SCHEDULE 
 PAYMENT SCHEDULE:

 Payment Schedule 
  

													
	 Project:
	  	CHS-0214-02	  	 	Total Direct Fees:	  	  	[***]	 			
	 Sponsor:
	  	Coherus Biosciences	  				  		 			
					
	 Payment #
	  	Payment
Description/Type	  	Invoice Date	 	  	Amount to
Pay	 	Percentage	 
	 [***]
	  	[***]	  	 	[***]	  	  	[***]	 	 	[***]	  
		  		  	 	Total Payments:	  	  	[***]	 	 	100.00	% 

 [***] of this Task Order [***] of the total Pre-funded Expenses are due. [***]. SPONSOR shall pay such invoice within [***] of
receipt. [***] received from SPONSOR, [***]. 
 Additionally, [***] of the total estimated Pass-through Costs are due [***]. Pass-through Costs will be
billed to SPONSOR [***]. 
 Pass-through Costs and Pre-funded Expenses 

Any sums quoted with respect to Pass-through Costs and Pre-funded Expenses [***]. While MEDPACE will [***]. Payments made to third parties are [***]. 

Pass-through Costs may include, but are not limited to, [***] 

  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 13 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

[***]. Costs associated with, [***] are as detailed in the table below. 
  

					
	 Item
	  	Cost*	  	 Description

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

  

	*	Currency is [***]. Costs are subject to change based on [***]. 

 MEDPACE will pass-through [***]. This will
include [***]. 
  

					
	 Item
	  	Cost	  	Description
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	

  

	*	Currency is [***] 

 Pre-funded Expenses 

Pre-funded Expenses may include, but are not limited to, [***]. 

  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 14 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

Investigator fees are [***]. The investigator fee amount [***]. The laboratory fee amount [***]. 

Additional Costs 
 [***] 

All Direct Fees are [***]. All such changes [***]. After staff are assigned, [***]. 

Inflation 
 [***] 

Currency and Exchange Rate 
 The currency of this Task
Order is United States Dollars 
 MEDPACE will invoice SPONSOR for Investigator payments [***]. The Direct Fees detailed in this Task Order were calculated
using the [***]. [***]. [***]. 
  

					
	 COUNTRY
	  	 CURRENCY
	  	
1 USD (as of DD-MMM-2013) 
=

	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]


  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 15 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.
	  	










 THERAPEUTICALLY SPECIALIZED CLINICAL DRUG DEVELOPMENT 

 

					
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]

 Applicable Taxes 
 All
Direct Fees, Pass-through Costs, and Pre-funded Expenses are quoted excluding any [***], which include but are not limited to [***], which may be payable to MEDPACE by SPONSOR. 

  

			
	 




	  	 Medpace Task Order 13

Coherus Biosciences, Inc.
 CHS02142
Start up
 Page 16 of 16



			
		
	 [***]  Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions.